The FDA on Thursday approved Takeda’s recombinant ADAMTS13, now to be marketed as Adzynma, for the treatment of the rare blood disorder congenital thrombotic thrombocytopenic purpura—the biopharma company’s second approval in as many days.
https://www.pharmalive.com/wp-content/uploads/2023/09/Takeda-Cambrige.jpeg350625Christiane Truelovehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngChristiane Truelove2023-11-10 08:30:162023-11-10 10:38:21Takeda wins first FDA approval for ultra-rare blood clotting disease
